Skip to content

Aromatherapy to Address Psychological Distress in Emergency Department Patients.

Aromatherapy to Address Psychological Distress in Emergency Department Patients.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07328412
Enrollment
60
Registered
2026-01-09
Start date
2026-01-30
Completion date
2026-03-30
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aromatherapy, Anxiety, Stress, Emergency Department

Brief summary

The goal of this clinical trial is to understand the feasibility and acceptability of a brief aromatherapy session for reducing stress, anxiety, and improving patient satisfaction among emergency department patients. The main question the study aims to answer is: Is the intervention acceptable and feasible? Participants in the intervention group will receive a lavender-scented tube and smell it for about 5 minutes. Participants in the control group will receive an unscented tube and follow the same instructions.

Detailed description

Stress and anxiety are frequently experienced by patients during emergency department (ED) visits, often due to diagnostic uncertainty, prolonged wait times, and environmental factors such as noise and bright lighting. These psychological stressors can trigger physiological responses, including elevated cortisol levels, increased blood pressure, and disrupted sleep, which may negatively impact patients' experiences and overall health outcomes. Aromatherapy has emerged as a promising non-pharmacologic intervention for reducing stress and anxiety in various settings. This pilot randomized controlled trial will be conducted to assess the feasibility and acceptability of a brief aromatherapy session for ED patients. Research staff will pre-screen potential participants admitted to the ED Observation Unit at Brigham and Women's Hospital (BWH) using information from the electronic medical record. After obtaining approval from the treating medical team, staff will approach and invite potential participants to participate in the study. Once consented and screened eligible, participants will complete a baseline assessment and be randomized in a 1:1 ratio to either the aromatherapy group or the control group. Participants in the aromatherapy group will receive a lavender-scented tube and be instructed to inhale it for about 5 minutes. Participants in the control group will receive an unscented tube and follow the same instructions. After the session, participants will complete a post-experiment assessment.

Interventions

A diffuser tube containing a cotton wick infused with 5 drops of lavender essential oil.

OTHERUnscented Aromatherapy

A diffuser tube containing a cotton wick saturated with 10 drops of water.

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults ≥18 years of age * Admitted to the BWH Emergency Department (ED) Observation Unit * Able to provide written informed consent * Willing to participate in a 1-hour aromatherapy session

Exclusion criteria

* Acutely ill and unable to be approached for research, as determined by the treating medical team and/or physician investigator * Active gastrointestinal problems at the time of enrollment (e.g., nausea, vomiting, abdominal cramping, diarrhea), as determined by the treating team and/or physician investigator. * Pregnancy or breastfeeding * Current or planned treatment using sedating medications * History of, or current presentation with, significant cognitive impairment or acute delirium that would preclude informed consent or participation * Currently receiving supplemental oxygen * Acute exacerbation of asthma or COPD * Admission for an acute upper or lower respiratory tract illness (e.g., pneumonia, bronchitis, influenza, COVID-19) * Known allergy or sensitivity to lavender * Documented history of anosmia (loss of smell) * Documented hypotension during current ED presentation, defined as systolic blood pressure \<90 mmHg * Assigned clinical staff (physician, nurse, or other healthcare provider) with fragrance sensitivity prior to consent * Concurrent enrollment in another interventional drug or behavioral trial * Any condition that, in the judgment of the treating team or physician investigator, would make study participation unsafe or inappropriate.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability of intervention via AIMday 1Acceptability will be assessed via the Acceptability of Intervention Measure (AIM). AIM is a 4-item Likert agreeability scale ranging from 1 (Completely disagree) to 5 (Completely agree). A mean score is calculated, resulting in a continuous score with higher scores indicating greater intervention acceptability.
Usability of intervention via SUSday 1Usability will be assessed via an adapted, validated 2-item version of the System Usability Scale (SUS). Each item is rated on a 5-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree). The mean score of each item will be calculated and entered into a validated regression equation to estimate the full SUS score, which ranges from 0 to 100, with higher scores indicating greater usability.

Contacts

Primary ContactPeter Chai, MD, MMS
pchai@bwh.harvard.edu6177325638
Backup ContactPeevara Srimanus, MPH
psrimanus@bwh.harvard.edu6177325638

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026